KROS
Price
$14.46
Change
+$0.08 (+0.56%)
Updated
Jul 25 closing price
Capitalization
587.3M
5 days until earnings call
MEOBF
Price
$0.96
Change
-$0.00 (-0.00%)
Updated
Jun 23 closing price
Capitalization
2.13B
32 days until earnings call
Interact to see
Advertisement

KROS vs MEOBF

Header iconKROS vs MEOBF Comparison
Open Charts KROS vs MEOBFBanner chart's image
Keros Therapeutics
Price$14.46
Change+$0.08 (+0.56%)
Volume$324.82K
Capitalization587.3M
Mesoblast
Price$0.96
Change-$0.00 (-0.00%)
Volume$1K
Capitalization2.13B
KROS vs MEOBF Comparison Chart in %
Loading...
KROS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MEOBF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
KROS vs. MEOBF commentary
Jul 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is KROS is a Hold and MEOBF is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 26, 2025
Stock price -- (KROS: $14.46 vs. MEOBF: $0.96)
Brand notoriety: KROS and MEOBF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: KROS: 57% vs. MEOBF: 108%
Market capitalization -- KROS: $587.3M vs. MEOBF: $2.13B
KROS [@Biotechnology] is valued at $587.3M. MEOBF’s [@Biotechnology] market capitalization is $2.13B. The market cap for tickers in the [@Biotechnology] industry ranges from $313.33B to $0. The average market capitalization across the [@Biotechnology] industry is $2.57B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

KROS’s FA Score shows that 1 FA rating(s) are green whileMEOBF’s FA Score has 0 green FA rating(s).

  • KROS’s FA Score: 1 green, 4 red.
  • MEOBF’s FA Score: 0 green, 5 red.
According to our system of comparison, KROS is a better buy in the long-term than MEOBF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

KROS’s TA Score shows that 6 TA indicator(s) are bullish while MEOBF’s TA Score has 4 bullish TA indicator(s).

  • KROS’s TA Score: 6 bullish, 4 bearish.
  • MEOBF’s TA Score: 4 bullish, 1 bearish.
According to our system of comparison, MEOBF is a better buy in the short-term than KROS.

Price Growth

KROS (@Biotechnology) experienced а +5.16% price change this week, while MEOBF (@Biotechnology) price change was 0.00% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.58%. For the same industry, the average monthly price growth was +17.35%, and the average quarterly price growth was +27.29%.

Reported Earning Dates

KROS is expected to report earnings on Oct 30, 2025.

MEOBF is expected to report earnings on Nov 26, 2025.

Industries' Descriptions

@Biotechnology (+7.58% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MEOBF($2.13B) has a higher market cap than KROS($587M). KROS YTD gains are higher at: -8.654 vs. MEOBF (-56.136). KROS has higher annual earnings (EBITDA): 14.8M vs. MEOBF (-77.78M). KROS has more cash in the bank: 721M vs. MEOBF (37.7M). KROS has less debt than MEOBF: KROS (18.4M) vs MEOBF (126M). KROS has higher revenues than MEOBF: KROS (215M) vs MEOBF (5.67M).
KROSMEOBFKROS / MEOBF
Capitalization587M2.13B28%
EBITDA14.8M-77.78M-19%
Gain YTD-8.654-56.13615%
P/E RatioN/AN/A-
Revenue215M5.67M3,792%
Total Cash721M37.7M1,912%
Total Debt18.4M126M15%
FUNDAMENTALS RATINGS
MEOBF: Fundamental Ratings
MEOBF
OUTLOOK RATING
1..100
43
VALUATION
overvalued / fair valued / undervalued
1..100
88
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
95
PRICE GROWTH RATING
1..100
65
P/E GROWTH RATING
1..100
58
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
KROSMEOBF
RSI
ODDS (%)
Bearish Trend 2 days ago
83%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
55%
Momentum
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
41%
MACD
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 2 days ago
55%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
52%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
51%
Advances
ODDS (%)
Bullish Trend 17 days ago
80%
N/A
Declines
ODDS (%)
Bearish Trend 27 days ago
82%
N/A
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
87%
N/A
Aroon
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
54%
View a ticker or compare two or three
Interact to see
Advertisement
KROS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MEOBF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
TEGIX46.02N/A
N/A
Touchstone Mid Cap Growth Inst
FRINX12.10N/A
N/A
Fidelity Advisor Real Estate Income A
IIGZX12.28N/A
N/A
Voya Global High Dividend Low Vol Port I
POIIX16.56N/A
N/A
Polen International Growth Institutional
RRSVX15.06N/A
N/A
RBC Small Cap Value R6

MEOBF and

Correlation & Price change

A.I.dvisor indicates that over the last year, MEOBF has been loosely correlated with SPHDF. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if MEOBF jumps, then SPHDF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MEOBF
1D Price
Change %
MEOBF100%
N/A
SPHDF - MEOBF
50%
Loosely correlated
N/A
AVTX - MEOBF
46%
Loosely correlated
+0.90%
COGT - MEOBF
39%
Loosely correlated
-0.98%
MESO - MEOBF
26%
Poorly correlated
-3.65%
KROS - MEOBF
26%
Poorly correlated
+0.56%
More